A Nutritional Evaluation of Vitamin E Status in Very Low Birth Weight Infants with Respect to Changes in Plasma and Red Blood Cell Tocopherol Levels

Hirohisa TANAKA, Makoto MINO,¹ and Tohru TAKEUCHI²

¹ Department of Pediatrics, Osaka Medical College, Takatsuki 569, Japan
² Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi 590–02, Japan
(Received February 2, 1988)

Summary Nutrition status of vitamin E was assessed in very low birth weight infants of less than 1,500 g, with respect to changes in plasma and red blood cell (RBC) tocopherol concentrations. The forty infants examined were divided into two groups in terms of their birth weight: group A, less than 1,000 g; and group B, 1,000–1,500 g. Immediately after birth, plasma tocopherol level was 335 ± 101 µg/dl in group A and 316 ± 103 µg/dl in group B, while RBC tocopherol was 187 ± 48 µg/dl and 231 ± 72 µg/dl packed RBCs, in groups A and B, respectively. In two infants, RBC tocopherol concentrations were less than 115 µg/dl, this level being reported as the lowest of the normal range. After birth, plasma and RBC tocopherol levels decreased markedly during 4 to 6 weeks of life especially in group A, while no decrease below normal range was documented in RBC levels in group B. A fine granule preparation of tocopherol nicotinate (20 mg/kg/day) was administered in seven other infants, three in group A and four in group B. All three infants in group A showed no elevation of plasma and RBC tocopherol levels during the first 4 or 5 weeks of the administration, but a marked elevation thereafter. In three of the four infants in group B, an elevation of plasma and RBC tocopherol concentrations was documented after 2 weeks of the administration. The above findings indicate that no deficiency exists even in very low birth weight infants immediately after birth, while the deficiency may develop after birth, due to a poor ability to absorb fat.

Key Words vitamin E, tocopherol, plasma, erythrocytes, neonate, lipid

As the assessment of human vitamin E status from a clinical standpoint has generally relied on serum or plasma tocopherol concentrations, it has been previously supposed that newborn infants are in a marginally vitamin E-deficient
state due to their low plasma tocopherol concentrations (1–3). However, estimations of nutritional vitamin E status based only on plasma levels are now recognized to be subject to error because the levels tend to fluctuate in relation to plasma lipids (4–6). Horwitt et al. (4) thus proposed plasma tocopherol expressed in terms of total lipids (tocopherol/lipid ratio) as a very reliable index of vitamin E status, and several clinical studies of the nutritional status of vitamin E have been undertaken, based on this index (4–6). Martinetz et al. (7) and Desai et al. (8) reported that this ratio in newborn infants appeared to be within an acceptable range (more than 0.8) (4), indicating that the newborn infants may not be deficient in vitamin E. On the basis of our findings on red blood cell (RBC) tocopherol, which is also thought to be an expression of vitamin E status (9–11), the majority of newborn infants showed a normal vitamin E status (12, 13). However, there is no precise information in very low birth weight infants, based on such new indices for the assessment of vitamin E status. Plasma tocopherol levels probably may underestimate nutritional status of vitamin E in neonates. This report deals with vitamin E status in very low birth weight infants. In addition, changes in plasma and RBC tocopherol levels were examined after oral administration of vitamin E to neonates, because a theoretical and experimental basis is being developed which advocates the use of parenteral tocopherol in pharmacological doses as a form of therapy to ameliorate or totally treat a variety of neonatal disorders (13–21), although some hazard and disappointing results have thus far been reported (22–25).

MATERIALS AND METHODS

Subjects. In the first study, forty newborn infants of very low birth weight were examined with respect to vitamin E status in our newborn nursery, from November 1984 to May 1985. Characteristics for the infants examined are documented in Table 1. Eleven other infants born in the same period were excluded from this study, because six infants were severely ill and five infants died. The infants examined were divided into two groups based on the birth weight—less than 1,000 g (group A), and 1,000–1,500 g (group B).

In the second study, oral administration of a vitamin E preparation was undertaken after May 1985 in seven other premature infants. Their profiles are shown in Table 2. None of the infants who were selected randomly had respiratory problems or feeding trouble during the examination periods.

The compositions of the human milk and formula used in this study are listed in Table 3. All premature infants were first fed their own mother’s milk by gastric gavage every 2 h. Feedings were begun when the infant was stable (all within 1 week of birth) at a volume of 20–30 ml/kg/day, increased by a similar amount daily so that all infants achieved 180 ml/kg/day within 2 weeks, and maintained by daily adjustments according to weight increase. If the mother’s milk was insufficient due to poor secretion, a formula (premature formula), listed in Table 3, was added until the infants’ body weight reached 1,500 g. After 1,500 g was attained, a formula
Table 1. Characteristics for subjects without vitamin E supplementation.

<table>
<thead>
<tr>
<th>Birth weight (g)</th>
<th>500–999</th>
<th>1,000–1,499</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numbers</td>
<td>14 (2a)</td>
<td>26 (16b)</td>
</tr>
<tr>
<td>Male : Female</td>
<td>6 : 8</td>
<td>13 : 13</td>
</tr>
<tr>
<td>Inborn: Transport</td>
<td>12 : 2</td>
<td>20 : 6</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>855 ±83</td>
<td>1,128 ±78c</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>27.2 ±1.3</td>
<td>30.1 ±2.2</td>
</tr>
<tr>
<td>AGA: SGAd</td>
<td>11 : 3</td>
<td>21 : 5</td>
</tr>
<tr>
<td>APGAR score 1 min</td>
<td>4.4 ±1.6</td>
<td>5.5 ±2.5</td>
</tr>
<tr>
<td>5 min</td>
<td>7.1 ±1.3</td>
<td>7.9 ±1.8</td>
</tr>
<tr>
<td>RDS</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Intraventricular hemorrhage (IVH)*</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>PDA</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>During oxygen therapy (days)</td>
<td>37.4 ±35.5</td>
<td>5.9 ±12.5</td>
</tr>
<tr>
<td>Days reached 120 kcal/kg/day</td>
<td>30.6 ±16.8</td>
<td>10.7 ±6.0</td>
</tr>
</tbody>
</table>

*500–749 g. b 1,000–1,249 g. c Mean ± SD. d AGA, appropriate for gestational age; SGA, small for gestational age, less than 10 percentile by classification of Lubuchenco (43). *IVH was diagnosed with echo and/or CT scanning.

Table 2. Characteristics of subjects with vitamin E supplementation.

<table>
<thead>
<tr>
<th>Infant</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth weight (g)</td>
<td>888</td>
<td>980</td>
<td>998</td>
<td>1,128</td>
<td>1,234</td>
<td>1,179</td>
<td>1,060</td>
</tr>
<tr>
<td>Gestational age (wks)</td>
<td>25</td>
<td>28</td>
<td>28</td>
<td>29</td>
<td>30</td>
<td>29</td>
<td>33</td>
</tr>
<tr>
<td>Sex</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td>APGAR score 1 min</td>
<td>9</td>
<td>6</td>
<td>4</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>5 min</td>
<td>10</td>
<td>9</td>
<td>7</td>
<td>9</td>
<td>5</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Growth</td>
<td>AGA</td>
<td>AGA</td>
<td>AGA</td>
<td>AGA</td>
<td>AGA</td>
<td>AGA</td>
<td>SGA</td>
</tr>
</tbody>
</table>

(regular formula) was used as an additional milk. An iron dosage of 6 mg/day was administered after 2 weeks of life. None of the infants had parenteral nutrition which contained tocopherol.

Gestational age was estimated by review of maternal records and confirmed by Dubowitz et al.’s examination (26).

Administration of vitamin E. The daily oral administration was undertaken after 2 weeks of life. The vitamin E used was a very fine granule preparation of dl-rac-alpha tocopheryl nicotinate (manufactured by Eisai Co., Ltd.) because of no increase in the osmolarity of the formula mixed preparation. The vitamin E preparation was suspended in a dosage of 10 mg/kg into the formula, which was Vol. 34, No. 3, 1988
Table 3. Composition of milks used in this study.

<table>
<thead>
<tr>
<th>Milks</th>
<th>Human milk</th>
<th>Formula</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Premature</td>
<td>Regular</td>
<td></td>
</tr>
<tr>
<td>Postpartum</td>
<td>&lt;1 wk</td>
<td>4–6 wks</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Sample numbers</td>
<td>5</td>
<td>8</td>
<td>2.18</td>
<td>3.60</td>
</tr>
<tr>
<td>Total lipids (mg/dl)</td>
<td>2.00</td>
<td>2.01</td>
<td>21</td>
<td>20</td>
</tr>
<tr>
<td>PUFA (%)</td>
<td>20</td>
<td>22</td>
<td>0.60</td>
<td>0.51</td>
</tr>
<tr>
<td>Alpha-tocopherol (mg/dl)</td>
<td>1.16</td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tocopherol/PUFA (mg/g)</td>
<td>2.9</td>
<td>1.0</td>
<td>1.3</td>
<td>0.7</td>
</tr>
</tbody>
</table>

The values represented are the mean values.

administered twice a day at 10:00 a.m. and 10:00 p.m. Blood was drawn every week immediately prior to feeding with the vitamin E-fortified formula.

The study protocol was approved by the ethics committee at the college hospital, and the studies were performed after informed consent had been obtained from the parents.

Collection and preparation of blood samples. Blood was collected into heparinized tubes. Three ml of heparinized blood was centrifuged at 3,000 rpm for 10 min, and the RBCs were separated from plasma and washed with three 10 ml portions of physiological saline. After the last washing, 0.6 ml of the packed RBCs was resuspended into the same volume of normal saline, a part of which was used for the tocopherol assay, and the remainder for hematocrit determination.

Analyses. Plasma separated from RBCs was used for analysis of tocopherol. Tocopherol in plasma and the RBCs was analyzed by high performance liquid chromatography (HPLC) using modified Ishibashi et al.'s method (27), as described in a previous report (12). The values in RBCs obtained from HPLC analysis were corrected by hematocrit values in each sample. In this study, only values for alpha-tocopherol are given unless otherwise stated. Plasma total lipid was measured by sulfo-phospho-vanillin method (28).

Lipids were extracted by Bligh and Dyer’s method (29) for milk analysis. Fatty acids of total lipids were interesterified into methyl esters with 3% HCl in methanol (97: 3, v/v) under nitrogen gas at 85°C for 2 h (30) with added internal standard (100 µg of n-eicosanoic acid). The methyl esters were extracted with hexane, evaporated, and then dissolved in acetone to be analyzed using a gas liquid chromatography (GLC), (Shimadzu GC-7A) with a FID. A glass column (3 mm × 3.1 m) packed with Shimalite (brown diatomite, 80–100 mesh, acid washed) as a support and containing 5% Shinchrom E-71 (polyester nitrile; Shimadzu Co., Ltd.) was used. Student’s t-test was used for statistical analysis.
VITAMIN E STATUS IN VLBW INFANTS

RESULTS

1. Tocopherol levels in plasma and RBCs at birth

With respect to blood samples collected during the first 24 h of life, plasma tocopherol levels were 335 ± 101 µg/dl in group A, and 316 ± 103 µg/dl in group B. RBC tocopherol levels were 187 ± 48 µg/dl in group A and 231 ± 72 µg/dl in group B. The relationship between gestational age (weeks) and plasma tocopherol levels, and between gestational age and RBC tocopherol levels are shown in Table 4. The former showed no relationship, while the latter showed a slightly positive correlation \( r = 0.40, p < 0.05 \). A correlation was also observed between birth weight and RBC tocopherol levels \( r = 0.35, p < 0.05 \), but not between birth weight and plasma tocopherol levels. Two infants had RBC tocopherol concentrations of below 115 µg/dl, this level being reported as the lowest of the normal range (12).

2. Changes in tocopherol levels in plasma and RBCs after birth

Figures 1 and 2 show changes in plasma and RBC levels after birth. In group A, at 4 weeks of postnatal age the RBC levels became below the lowest normal range level (115 µg/dl), and then the low levels were maintained until 7 weeks of life. A remarkable increase was shown after 11 weeks of life. Plasma levels in group A immediately lowered after birth and reached the lowest level at 2 to 3 weeks of life. Plasma levels usually remained below the lowest normal level of 450 µg/dl throughout the periods examined. In group B, RBC tocopherol levels were mostly maintained above 115 µg/dl, although in this group the levels also lowered at 2 to 4 weeks of life. Plasma levels also usually remained below 450 µg/dl. Since development of the absorption mechanism of the vitamin may relate to post-conceptional ages, we further examined tocopherol changes in blood as a function of the gestational ages. When the groups were classified in terms of gestational age—less than 30 weeks (28.0 ± 1.7 wks: M ± SD), and 30 or more weeks (31.8 ± 1.6 wks: M ± SD)—the plasma tocopherol was found to remarkably increase immediately after birth in the group of 30 or more gestational weeks, while in the less than 30 weeks group the level remained below 450 µg/dl for a long period (Figs. 3 and 4). In the group of longer gestation, RBC levels decreased until 2 weeks of life (cor-

Table 4. Correlation between gestational age or birth weight and blood tocopherol levels immediately after birth.

<table>
<thead>
<tr>
<th>Correlation</th>
<th>n</th>
<th>r</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age vs. plasma</td>
<td>35</td>
<td>-0.05</td>
<td>n.s.*</td>
</tr>
<tr>
<td>vs. RBC</td>
<td>34</td>
<td>0.40</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Birth weight vs. plasma</td>
<td>36</td>
<td>-0.11</td>
<td>n.s.</td>
</tr>
<tr>
<td>vs. RBC</td>
<td>34</td>
<td>0.35</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

* n.s., not significant.
responding to 32 weeks of post-conceptional age), and thereafter there was a rise which coincided with that of the plasma level. On the other hand, in the group of shorter gestation the plasma and RBC tocopherol levels decreased and remained still at the lowest level at 11 weeks of life.
Fig. 3. Changes in plasma tocopherol in very low birth weight infants after birth in terms of gestational age. The values are represented as the mean ± SD. Open circles show the values in the group of less than 30 weeks gestation (28.0 ± 1.7 wks: M ± SD) and closed circles show those in another group of 30 or more weeks (31.8 ± 1.6 wks: M ± SD). * Significant difference (p < 0.001), ** (p < 0.005).

Fig. 4. Changes in RBC tocopherol in very low birth weight infants after birth in terms of gestational age. The values are represented as the mean ± SD. Open and closed circles are the same as those in Fig. 3. * Significant difference (p < 0.001), ** (p < 0.002).

3. Administration with vitamin E preparation

Changes in plasma and RBC tocopherol levels were examined in seven infants, as shown in Figs. 5 and 6. The three infants corresponding to group A showed no elevation of their plasma and RBC tocopherol levels during the first 4 or 5 weeks of the administration. However, this was followed by a prompt and marked elevation
Fig. 5. Changes in plasma and tocopherol levels in group 1 infants (less than 1,000 g birth weight) after administration of dl-alpha tocopherol nicotinate after 2 weeks of life. Open circles show the values in RBC, and closed circles show those in plasma.
Fig. 6. Changes in plasma and tocopherol levels in group 2 infants (1,000–1,500 g) after administration of dl-alpha tocopheryl nicotinate after 2 weeks of life. Open and closed circles are the same as those in Fig. 5.
in both plasma and RBC levels during 6 to 8 weeks of life. Among the four infants corresponding to group B, an elevation of plasma and RBC tocopherol concentrations was documented in three infants after 2 weeks of the administration, whereas in the fourth infant, no elevation was shown until 8 weeks of life, as in group A. In all of the infants, changes in RBC tocopherol levels were almost parallel with those in plasma levels. After the tocopheryl nicotinate administration in a dosage of 20 mg/kg/day, the elevated maximum plasma levels were within usual adult levels (less than 2,000 µg/dl), while the maximum RBC tocopherol levels reached levels higher than the upper normal level (320 µg/dl) (12) in three of the four infants in group B.

4. Correlation between RBC tocopherol and plasma tocopherol/total lipid ratios

Correlation of RBC tocopherol levels to the tocopherol/lipid ratios was examined only in limited cases of the premature infants. Total lipids were distributed from 233 to 636 mg/dl (381 ± 92 mg/dl: M ± SD) in the infants, within 2 months of life. As shown in Fig. 7, RBC tocopherol levels were very closely correlated with the ratios ($r = 0.88$, $p < 0.001$, $n = 36$).

DISCUSSION

In classical investigations, it has been believed that newborn and premature infants are marginally deficient in vitamin E, because of their low plasma tocopherol

levels and the increased susceptibility of their RBCs to hydrogen peroxide stress. In addition, this assumption also comes from the finding that the transportation of tocopherol from mother to fetus may be impaired, given that plasma tocopherol concentrations in cord blood are extremely low, as compared with those in the mother (31, 32). However, it is well known that plasma tocopherol levels closely related to plasma total lipids (4-6), while the hydrogen hemolysis test lacks specificity and reproducibility (33, 34). Martinetz et al. (7) and Desai et al. (8) reported that low plasma tocopherol concentrations in neonates were due to a low plasma lipid level, rather than a true deficiency of vitamin E. The tocopherol/lipid ratios, proposed by Horwitt et al. (4) as an expression which represents the most reliable index routinely available in humans, have not yet been precisely investigated in the low birth weight infants. Thus, vitamin E status in neonates has not yet been clearly established. Although our previous study reported a close correlation between the tocopherol/total lipid ratios and RBC tocopherol concentration in a population survey in Japanese children (12), it was also confirmed again in the very low birth weight infants in this study (Fig. 7). We have previously further confirmed that RBC tocopherol concentrations reflect tocopherol concentrations in liver tissues, especially the concentrations in the subcellular fractions, as the nutritional status of vitamin E varies in rats (11, 35). From this study of vitamin E status based on RBC tocopherol in very low birth weight premature infants, it appeared that even in such infants, no vitamin E deficiency exists immediately after birth, because the RBC tocopherol concentrations were proportional to the normal values, which have previously been reported as 176±9 μg/dl (M±SEM, ranging from 101 to 243 μg/dl) (12). If there is no vitamin E deficiency in very low birth weight infants at birth, the mechanism for tocopherol transportation from mother to fetus remains to be elucidated. Tanaka and Mino (36) recently reported on the possibility of cell-to-cell transfer to tocopherol other than through the lipoproteins transportation. Therefore, such a mechanism may play a role in transportation through the placenta. In the very low birth weight infants with less than 1,000 g (group A), the plasma and RBC tocopherol concentrations, however, gradually decreased during the neonatal period after birth, as compared with the infants weighing 1,000-1,500 g (group B), even though daily tocopherol intake remained with an adequate tocopherol/PUFA ratio after birth, as shown in Table 3. Such a result could be attributable to a poor ability to absorb lipids (including vitamin E) in milk. This hypothesis was supported by the subsequently observed changes in plasma and RBC tocopherol concentrations after administration with tocopheryl nicotinate, as shown in Fig. 5. Despite the intake of a large amount of a vitamin E preparation, no increase in tocopherol in plasma and RBCs was observed during the first 4 to 5 weeks of administration (corresponding to 6-7 weeks of life and 31-32 weeks of post-conceptional age), indicating a poor absorption of vitamin E, especially in the infants of less than 1,000 g birth weight. However, a prompt increase in plasma and RBC tocopherol concentrations at 32-35 weeks of post-conceptional ages, indicated that the absorption mechanism had developed. There have been conflicting
reports (37-39) suggesting that orally administered tocopherol could be absorbed in very low birth weight infants. However, it is difficult to compare the available data because infants were of various birth weights, and may have received different tocopherol preparations. In our study, plasma tocopherol levels changed within a deficient range of below 500 μg/dl (40). Since RBC tocopherol concentration is known to be almost constant regardless of age (12), a finding that the RBC tocopherol concentrations in the very low birth weight infants decreased below the lowest limit of normal range, seems to indicate that vitamin E deficiency developed in this period. The infants with more than 1,000 g birth weight (group B), on the other hand, showed no reduction of RBC tocopherol concentrations below normal range during the respective periods, indicating the development of a normal absorption mechanism for maintaining vitamin E status. Thus, for the nursing of premature infants, the risk of vitamin E deficiency should still be considered, especially in very low birth weight infants, until their fat absorption mechanism develops.

It is well known that dietary vitamin E requirement (which usually directly reflects dietary fatty acids) increases a PUFA composition increases in situ (41, 42). In this study, PUFA composition and lipid content were examined in eight randomly stocked breast milk samples. Colostrum in preterm mothers did not significantly differ from their mature milk, with regard to lipid content and PUFA composition, while tocopherol content in colostrum was higher than in the mature milk. A formula for premature infants had similar constituents regarding lipid content and PUFA composition, and thus did not significantly differ from those in a regular formula. Therefore, tocopherol changes observed in the infants in this study may not be due to different milk series.

In the second investigation of vitamin E administration, the elevated RBC tocopherol levels were much higher than those assumed on the basis of plasma levels, after the absorption mechanism developed. A large amount of tocopherol in RBCs found in this study is probably due to a low level of plasma lipoproteins. Similar transportation is thus expected to occur in tissues, as assumed in our previous reports (11, 34). Recently, several reports (22-25) have warned of vitamin E toxicity including an increased incidence of necrotizing enterocolitis (NEC) and sepsis in low birth weight infants who received pharmacological doses of vitamin E preparation as a therapy for retrolental fibroplasia (RLF) (22-25). In these risk cases, plasma tocopherol concentrations were reported to exceed 3.5 mg/dl (21). The level of 3.5 mg/dl has been thought to be within the adult physiological range in these reports. In our present study on changes in RBC tocopherol after administration, RBC tocopherol concentrations markedly exceeded the adult physiological range (12), even though plasma tocopherol concentrations were within 2 mg/dl. This finding suggests that the tocopherol concentration must elevate to extremely unusual concentrations at the effective sites of biomembrane, as plasma tocopherol exceeds 3.5 mg/dl. This may cause unpredictable effects in premature infants. Therefore, the risks in administering large dosages of tocopherol preparations

should be carefully considered in such newborn infants, even if their plasma tocopherol concentrations do not exceed the adult physiological level.

A Grant-Aid (61480225) for Scientific Research from the Ministry of Education, Science, and Culture, Japan, and a Grant for Maternal and Child Health Research from the Ministry of Health and Welfare, Japan.

REFERENCES


VITAMIN E STATUS IN VLBW INFANTS


